Daratumumab Infusion Acceleration

Trial Profile

Daratumumab Infusion Acceleration

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Daratumumab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 22 Feb 2017 Planned primary completion date changed from 1 May 2017 to 31 May 2019.
    • 22 Feb 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top